Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual-care arm) with fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 males (aged 18-40 years) with at least 3 episodes of SCA-related priapism in the past 12 months. Priapism data were obtained via daily text messages to the participants. The trial’s primary outcome measures were 100% recruitment, 98.4% retention, and 93.5% adherence rates. Over a median of 10 months (interquartile range, 3-12), 2.5 and 3.02 priapism events per participant-month were recorded in the usual-care and the experimental arms, with an incidence rate ratio of 0.8 (95% confidence interval [CI], 0.3-1.9; P = .654). The rates of serious adverse events (P = .999) and hospitalization (P = .289) were similar in the 2 arms. Sperm concentration, motility, and normal morphology significantly decreased on hydroxyurea therapy but recovered to prehydroxyurea levels 3 months after therapy cessation. Post hoc, single-arm, pre-post analysis showed a 58.3% priapism incidence rate reduction in the usual-care arm (5.9-2.5 events per month; difference, 3.4; 95% CI, 1.1-5.8; P = .005) and a 66.3% priapism reduction in the experimental arm (8.9-3.02 events per month; difference, 5.9; 95% CI, 3.4-8.5; P < .001) compared with the prerandomization rates. A randomized controlled trial for priapism prevention is feasible in men with SCA. This trial was registered at www.clinicaltrials.gov as #NCT05142254.
1 October 2024 in Journal of Global Health Reports
Background: Increased paternal involvement during childbirth can enhance maternal and neonatal outcomes. However, in resource-constrained settings, cultural and health system factors often hinder the involvement of fathers in the birthing process. This study aimed to identify the factors influencing antenatal clients’ attitudes toward their partner’s presence during childbirth in northern Nigeria. Methods: We administered a pre-tested, culturally adapted questionnaire to antenatal clients at a tertiary health facility (n=351). Attitudinal scores were measured on a Likert scale, and logistic regression was used to compute adjusted odds ratios (aORs) for predictors. Results: Only 15.4% of respondents agreed or strongly agreed with the presence of their male partner during childbirth. Women opposed or strongly opposed the suggestion that their partner’s presence provided emotional support (35.9% and 59.8%, respectively), reduced labor pain perception (45.1% and 33.1%, respectively), strengthened the couple’s relationship (40.2% and 52.7%, respectively), or enhanced father-child bonding (32.3% and 46.6%, respectively). More than half of the respondents (57.0%) strongly disagreed that their partner’s presence enhanced paternal responsibility. Rather, the presence of the partner was considered unhelpful (49.3%), culturally unacceptable (37.9%), and against religious rulings (51.6%). Younger maternal age (<30 years, aOR=7.6, 95% CI=2.12-14.40) and higher parity (≥5 children, aOR=2.08, 95% CI=1.21-8.38) were associated with a more positive attitude towards the presence of the father during labor. Conclusions: Most women did not favor having their partners present during childbirth. Policymakers and healthcare providers should integrate cultural sensitivity considerations into guidelines and initiatives that promote male involvement in childbirth in similar settings.